PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.
Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).
A panel at the 2016 San Antonio Breast Cancer Symposium discussed the state of research and treatment of triple negative breast cancer (TNBC).
Tobacco industry representatives are continuing to meet with and are attempting to influence government officials in many countries.
Addition of ganetespib to docetaxel does not improve efficacy for salvage therapy in patients with advanced stage non-small cell lung cancer (NSCLC).
First-line ceritinib achieved statistically significant and clinically meaningful improvement in median progression-free survival (PFS).
Pembrolizumab is associated with a clinically-meaningful improvement in health-related quality of life.
The Trans-Pacific Partnership Agreement (TPPA) contains provisions for tobacco products that threaten public health.